Tibolone

Drug Profile

Tibolone

Alternative Names: Boltin; KB 889; Livial; Liviella; Livifem; ORG OD 14; Paraclim; Xyvion

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nourypharma; Organon
  • Developer Organon
  • Class Hormonal replacements; Norpregnenes; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 25 Jan 2018 Tibolone licensed to Grunenthal for commercialisation and distribution in Brazil, Central America, Colombia, Mexico and Peru
  • 15 Dec 2016 Biomarkers information updated
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote tibolone in South Korea for Menopausal syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top